BioCryst scraps $200M offering after seeing share price slide

BioCryst was ready for the public markets, but after shares sank 14% in the wake of the announcement, the rare disease company is making a U-turn.

The company has withdrawn a proposed $200 million public offering after deciding “current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders.”